New Delhi: ICMR National Task Force for Covid-19 has decided to oppose the Molnupiravir antivirus drug in the clinical management protocol for Covid-19 until now, the official source said on Tuesday.
Experts The task force quoted security issues and argued that Molnupiravir was not many benefits in Covid treatment to arrive at the decision in the meeting held on Monday.
According to the Ministry of Health, Molnupiravir is an antivirus drug that inhibits SARS-COV-2 replication by the mutagenesis virus.
This anti-covid pill received a drug regulator General Indian approval on December 28 for limited use in an emergency.
“Members of the National Task Force for Covid-19 do not support including drugs in the National Medicine Guidelines who quote that it does not have many benefits in the treatment of Coronavirus infection and that there is a security problem,” the official source of PTI.
The Head of the Indian Medical Research Council (ICMR) Dr.
Balram Bhargava has last week said that Molnupiravir has a major safety problem.
He added that who and England have not put it for treatment.
“We must remember that this drug has a major safety problem.
It can cause teratogenicity, mutagenicity and damage to cartilage.
It can damage the muscles too.” Contraception must be made for three months for men and women given because children born can be problematic due to teratogenic influences, “he said.
British medicines and the health care product supervisory agency on December 4 given approval for Molnupiravir under special conditions for Covid treatment -19 lightweight that has at least one of the risk factors to develop severe diseases.
USFDA on December 23 is given using emergency authorization for drugs to treat mild to moderate Covid-19 in high-risk adults for severe disease progress, including hospitalization or death , And for whom the alternative treatment of the choice is not accessible or the right clinical.
According to the condition, the drug must be sold by retail only below the recipe from a specialist who is recommended that the recommended dose must be 800 mg twice a day for five days.
Molnupiravir is not included in the Covid-19 clinical management protocol like now
